← Back to Search

Anti-metabolites

Chemotherapy + Vaccine Therapy for Non-Hodgkin's Lymphoma

Phase 3
Waitlist Available
Research Sponsored by Genitope Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No prior corticosteroids for lymphoma
Performance status ECOG 0-2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is comparing two different ways to treat non-Hodgkin's lymphoma.

Who is the study for?
This trial is for adults with stage III or IV follicular B-cell non-Hodgkin's lymphoma. Participants must have at least one measurable lesion, no other cancers in the past 5 years (except certain skin cancers or cervical carcinoma in situ), no autoimmune diseases, not be pregnant/nursing, and use effective contraception. They should not have had previous cytotoxic therapy for lymphoma or certain other treatments.Check my eligibility
What is being tested?
The study is testing how well a combination of chemotherapy followed by vaccine therapy plus sargramostim works against advanced non-Hodgkin's lymphoma. Patients are randomly assigned to receive different regimens to see which one might be more effective in treating their cancer.See study design
What are the potential side effects?
Chemotherapy can cause side effects like nausea, hair loss, fatigue, and increased risk of infection. Vaccine therapy may lead to injection site reactions and flu-like symptoms. Sargramostim often causes bone pain, fever, muscle aches, and sometimes allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have not taken corticosteroids for lymphoma.
Select...
I can take care of myself and perform daily activities.
Select...
I have not received antibody therapy for my lymphoma.
Select...
I have not had chemotherapy for lymphoma.
Select...
I am 18 years old or older.
Select...
My lymphoma is at an advanced stage and confirmed by a biopsy.
Select...
I have at least one tumor that can be measured on scans, besides the one biopsied.
Select...
My cancer has not spread to my brain or spinal cord.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Genitope CorporationLead Sponsor
5 Previous Clinical Trials
88 Total Patients Enrolled
4 Trials studying Lymphoma
2 Patients Enrolled for Lymphoma
David HindsStudy ChairGenitope Corporation
1 Previous Clinical Trials
30 Total Patients Enrolled

Media Library

Chemotherapy (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT00017290 — Phase 3
Lymphoma Research Study Groups:
Lymphoma Clinical Trial 2023: Chemotherapy Highlights & Side Effects. Trial Name: NCT00017290 — Phase 3
Chemotherapy (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00017290 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the FDA sanction this medication?

"The safety of this intervention falls on the 3rd tier of our 1-to-3 scale because it is a Phase 3 trial. This means that, in addition to some data supporting efficacy, there are multiple rounds of data affirming its safety."

Answered by AI

Is this clinical trial widely available in Canada?

"This study is currently being conducted at 24 research centres, including ones in Denver, Dublin and Boise. If you are interested in participating, it would be ideal to choose the site that is closest to your home in order reduce travel costs and time."

Answered by AI

Are patients being enrolled in this experiment at present?

"No, this specific trial is not looking for patients at the moment. According to clinicaltrials.gov, the last time it was updated was December 3rd, 2013. There are, however, 1,789 other trials that are currently recruiting patients."

Answered by AI
~14 spots leftby Mar 2025